3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
92
Fallopian Tube Neoplasms
25
Breast Neoplasms
21
Endometrial Neoplasms
19
Carcinoma, Ovarian Epithelial
12
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Neoplasms
6
Fanconi Anemia, Complementation Group D1
5
Uterine Cervical Neoplasms
4
Recurrence
4
Neoplasm Metastasis
4
Carcinoma, Renal Cell
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Peritoneal Neoplasms
2
Ovarian Diseases
2
Carcinosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Relapsed Ovarian Cancers Patients
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Platinum-sensitive Ovarian Cancer
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Interventions
olaparib
1
liposomal doxorubicin
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasm Epithelial
×
olaparib
×
Gynecologic
×
Clear all
NCT04780945
2026-02-17
FAB
Leiden University Medical Center
Phase 2
Terminated
27 enrolled